ArticleOncology letters2014
Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma.Acta neuropathologica communications · 2026Article
- GABA treatment promoting cell apoptosis in meningioma correlates with EGFR/BCL-2/BAX axis.Journal of neuro-oncology · 2025Article
- The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.Journal of neuro-oncology · 2025Review
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- A novel BRAF::PTPRN2 fusion in meningioma: a case report.Acta neuropathologica communications · 2023Article
- Molecular classification and grading of meningioma.Journal of neuro-oncology · 2023Review
- Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients.Frontiers in neurology · 2023Article
- Recent advances in the molecular prognostication of meningiomas.Frontiers in oncology · 2022Review
- Hypothalamic RaxNature communications · 2021Article
- Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies.Oncotarget · 2020Article
- Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.Histology and histopathology · 2020Article
- Molecular characteristics of meningiomas.Journal of pathology and translational medicine · 2020Review
- Proteomic analysis of meningiomas reveals clinically distinct molecular patterns.Neuro-oncology · 2019Article
- Linear Accelerator-Based Radiosurgery of Grade I Intracranial Meningiomas.World neurosurgery: X · 2019Article
- Article
- Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.Neuro-oncology · 2016Article
- PIK3CA mutations in meningioma.Neuro-oncology · 2016Article
- Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.Journal of neuropathology and experimental neurology · 2015Article
- KINOMIC ALTERATIONS IN ATYPICAL MENINGIOMA.Medical research archives · 2015Article
- Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are among the most frequent intracranial tumors. Treatment involves surgical resection with optional subsequent radiotherapy for high-grade meningiomas or radiosurgery following incomplete tumor removal. At present, no pharmacological agents are used as treatment. The use of targeted therapies has been considered, and specific therapies, including anti-EGFR treatment, have been clinically tested. The experience from the treatment of various types of cancers shows that patient outcome depends on the mutational status of particular molecules, including epithelial growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α (PIK3CA). Therefore, the aim of the present study was to assess the occurrence and potential use of these markers in patients with meningioma. In total, 55 formalin-fixed, paraffin-embedded meningioma samples were subjected to genomic sequencing of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.